SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
BMY - short
BMY
|
|
|
-1.26%
in
2 days
(closed on 07/28/09)
shorting this...cover at 23.01....think we can get 28% return w/n six months...very tight stop at 23.01....
|
FDA Calendar Updates at BioMedReports.com
BMY
|
|
|
+11.73%
in
139 days
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-st...
|
FDA Calendar Updates – Diabetes: AZN, BMY, NVO, Takeda
BMY
|
|
|
+5.13%
in
63 days
(closed on 06/25/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA ...
|
FDA, Clinical Trial Calendar Updates: Weight Loss, Diabetes, and More
BMY
|
|
|
-9.68%
in
22 days
(closed on 04/23/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 110 entries through 4/1/09. The FDA Calendar includes the following information: company name, ticker, decision d...
|
Upcoming FDA Advisory Panel Meetings
BMY
|
|
|
+16.34%
in
23 days
(closed on 04/01/09)
A trio of diabetes drug candidates are affected by a tougher stance at the FDA for this class of drugs, which is focused on cardiovascular risks such as heart attack and stroke. Two of the drugs will be reviewed at early April FDA advisory panel meeting while a third will likely require additional clinical trials. http://www.biomedreports.com/fda-calendar.html <> In December the FDA issued a new guidance document that recommended more stringent clinical trials for diabetes drugs to better assess heart attack and stroke risks. In a change that was effective immediately,...
|
From the Blogosphere
Notable ETF Movers: PGM, XLV, SMH Up; UNG, KRE, FXI, AGQ, XME Down
|
StreetInsider.com Notable ETF Movers:HIGHER:<> iPath DJ AIG Platinum TR Sub-Idx ETN (NYSE: PGM) Up 6.10%, as platinum futures are down about 1.4%. Investors might be looking for exposure in a different metals other than gold and silver, as many commodities have been having a good year so far.
Health Care Select Sector SPDR (NYSE: XLV) up about 0.50%. Major holdings include Johnson & Johnson (NYSE: JNJ), Bristol Meyers (NYSE: BMY), and Pfizer (NYSE: PFE). Bristol Meyers announced a deal to develop Alder's arthritis drug today.
<> Semiconductor HOLDRs (NYSE: SMH) up 0.4% today. There were ...
|
Big Pharma & Biotech – Industry Outlook
|
|
|
The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses.
According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic co...
|
Big Pharma & Biotech – Zacks Analyst Interviews
|
|
|
The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses.
According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic co...
|
Big Pharma and Biotech – Industry Outlook
|
|
|
The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses.
According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic co...
|
Dividend Portfolio – October 2009 Update
|
|
|
 On the first Friday of every month, we will screen our database for the 10 companies with the highest dividend yield that are suitable for the enterprising investor. These 10 companies will be placed in a mock portfolio and rebalanced to have a 10% allocation to each company. The starting value of the portfolio is $100,000.00. Dividends will be reinvested in the portfolio.
To see the portfolio, you can view this google spreadsheet. This month’s screen resulted in the following companies being targeted. <>Psychemedics Corp (PMD) – 23.38%B&G Foods Inc (BGS) – 8.45%<><>National Presto Indus...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About BristolMyers Squibb Company
- Answers.com
